Published in Pharmacol Ther on April 03, 2013
Resveratrol for Alzheimer's Disease | NCT01504854
Cilostazol Augmentation Study in Dementia | NCT01409564
18-Month Study of Curcumin (Curcumin) | NCT01383161
Safety Study of Nicotinamide to Treat Alzheimer's Disease | NCT00580931
Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine (2015) 0.94
Hypomethylation of the IL17RC promoter in peripheral blood leukocytes is not a hallmark of age-related macular degeneration. Cell Rep (2013) 0.86
Acetyltransferases (HATs) as targets for neurological therapeutics. Neurotherapeutics (2013) 0.83
Gestational hypoxia and epigenetic programming of brain development disorders. Drug Discov Today (2014) 0.80
The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity? Dialogues Clin Neurosci (2014) 0.80
Curcumin inhibits the AKT/NF-κB signaling via CpG demethylation of the promoter and restoration of NEP in the N2a cell line. AAPS J (2014) 0.80
Therapeutic perspectives of epigenetically active nutrients. Br J Pharmacol (2014) 0.80
Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response. Int J Mol Sci (2015) 0.79
Nutraceutical Properties of Olive Oil Polyphenols. An Itinerary from Cultured Cells through Animal Models to Humans. Int J Mol Sci (2016) 0.77
Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes. Comput Struct Biotechnol J (2015) 0.76
Monoaminergic neuropathology in Alzheimer's disease. Prog Neurobiol (2016) 0.76
Epigenetic modulation of Cdk5 contributes to memory deficiency induced by amyloid fibrils. Exp Brain Res (2014) 0.76
DNA Demethylation Upregulated Nrf2 Expression in Alzheimer's Disease Cellular Model. Front Aging Neurosci (2016) 0.76
Developmental lead exposure and lifespan alterations in epigenetic regulators and their correspondence to biomarkers of Alzheimer's disease. Alzheimers Dement (Amst) (2016) 0.75
The epigenome in Alzheimer's disease: current state and approaches for a new path to gene discovery and understanding disease mechanism. Acta Neuropathol (2016) 0.75
Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease. Mol Ther (2017) 0.75
Instability in X chromosome inactivation patterns in AMD: a new risk factor? Med Hypothesis Discov Innov Ophthalmol (2013) 0.75
Chromatin modifications and their function. Cell (2007) 55.98
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell (1999) 25.75
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet (2003) 25.57
CpG-rich islands and the function of DNA methylation. Nature (1986) 24.90
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet (1999) 22.84
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (1998) 18.36
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 16.77
A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A (1975) 15.35
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80
Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci (2006) 13.32
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet (1998) 13.27
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
MeCP2, a key contributor to neurological disease, activates and represses transcription. Science (2008) 10.11
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Perceptions of epigenetics. Nature (2007) 8.43
The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol (2011) 8.15
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (1998) 7.43
Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13
Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature (1995) 7.11
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov (2002) 6.97
HDAC2 negatively regulates memory formation and synaptic plasticity. Nature (2009) 6.96
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem (2001) 6.85
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
Recovery of learning and memory is associated with chromatin remodelling. Nature (2007) 6.72
Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov (2012) 6.70
Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One (2010) 6.38
Covalent modification of DNA regulates memory formation. Neuron (2007) 6.20
Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem (2004) 5.99
Histones and histone modifications. Curr Biol (2004) 5.78
Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med (2008) 5.62
2012 Alzheimer's disease facts and figures. Alzheimers Dement (2012) 5.43
CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron (2004) 5.40
Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol (2003) 5.27
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A (2008) 5.24
Alzheimer mechanisms and therapeutic strategies. Cell (2012) 5.24
Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science (1992) 5.22
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem (2004) 5.14
Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat Neurosci (2010) 5.12
Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J Neurosci (2007) 5.02
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist (2007) 4.95
CREB and memory. Annu Rev Neurosci (1998) 4.76
2013 Alzheimer's disease facts and figures. Alzheimers Dement (2013) 4.75
SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J (2007) 4.66
The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci (2008) 4.28
5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci (2011) 4.15
beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci (1992) 4.10
CREB phosphorylation and dephosphorylation: a Ca(2+)- and stimulus duration-dependent switch for hippocampal gene expression. Cell (1996) 4.08
Broad thumbs and toes and facial abnormalities. A possible mental retardation syndrome. Am J Dis Child (1963) 4.07
The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci (2001) 3.92
Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis (2008) 3.84
Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging (2011) 3.83
Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology (2009) 3.64
Retracted SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell (2010) 3.58
Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J Biol Chem (2006) 3.47
Why schizophrenia genetics needs epigenetics: a review. Psychiatr Danub (2012) 3.38
Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn Mem (2005) 3.37
DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One (2007) 3.30
Antidepressant actions of histone deacetylase inhibitors. J Neurosci (2009) 3.17
Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron (2010) 3.15
Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem (2004) 3.13
Sp1 transcription factor binds DNA and activates transcription even when the binding site is CpG methylated. Genes Dev (1988) 3.05
Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry (2006) 3.00
The human histone deacetylase family. Exp Cell Res (2001) 2.86
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J (2003) 2.81
Betaine in human nutrition. Am J Clin Nutr (2004) 2.78
MeCP2 dysfunction in Rett syndrome and related disorders. Curr Opin Genet Dev (2006) 2.71
Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem (2002) 2.67
An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature (2012) 2.67
DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity. Neurobiol Learn Mem (2007) 2.56
microRNA-34c is a novel target to treat dementias. EMBO J (2011) 2.44
Epigenetics at the epicenter of modern medicine. JAMA (2008) 2.42
Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum Mol Genet (1999) 2.32
DNA methylation and memory formation. Nat Neurosci (2010) 2.31
Histone methylation regulates memory formation. J Neurosci (2010) 2.30
Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol (2008) 2.29
Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (2009) 2.27
Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation. PLoS One (2010) 2.26
The genetics of Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.20
Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics. Exp Neurol (2011) 2.20
Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci (1993) 2.12
Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res (1992) 2.10
ERK/MAPK regulates hippocampal histone phosphorylation following contextual fear conditioning. Learn Mem (2006) 2.08
Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry (2005) 2.04
Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One (2008) 2.01
The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun (2011) 2.00
In vivo activity of murine de novo methyltransferases, Dnmt3a and Dnmt3b. Mol Cell Biol (1999) 1.99
Preventing Alzheimer's disease. Science (2012) 1.94
The NIH Roadmap Epigenomics Program data resource. Epigenomics (2012) 1.93
Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci (2008) 1.92
Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron (1998) 1.90
Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci (2008) 1.88
Exploring and explaining epigenetic effects. Trends Genet (1997) 1.87
Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther (2008) 1.86
Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology (2009) 1.84
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst (2006) 1.83
Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci (2008) 1.92
The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci (2005) 1.46
Exposure to lead and the developmental origin of oxidative DNA damage in the aging brain. FASEB J (2006) 1.22
How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD. Curr Alzheimer Res (2007) 1.15
Gene expression profiles in the cerebellum and hippocampus following exposure to a neurotoxicant, Aroclor 1254: developmental effects. Toxicol Appl Pharmacol (2008) 1.11
Infant exposure to lead (Pb) and epigenetic modifications in the aging primate brain: implications for Alzheimer's disease. J Alzheimers Dis (2011) 1.06
Genome-wide expression and methylation profiling in the aged rodent brain due to early-life Pb exposure and its relevance to aging. Mech Ageing Dev (2012) 1.03
The environment, epigenetics and amyloidogenesis. J Mol Neurosci (2007) 1.03
In vitro Pb exposure disturbs the balance between Aβ production and elimination: the role of AβPP and neprilysin. Neurotoxicology (2011) 0.92
Lifespan profiles of Alzheimer's disease-associated genes and products in monkeys and mice. J Alzheimers Dis (2009) 0.89
Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model. Biogerontology (2008) 0.88
Enhanced taupathy and AD-like pathology in aged primate brains decades after infantile exposure to lead (Pb). Neurotoxicology (2013) 0.87
Alzheimer's disease biomarkers and epigenetic intermediates following exposure to Pb in vitro. Curr Alzheimer Res (2012) 0.87
Integration of genome-wide expression and methylation data: relevance to aging and Alzheimer's disease. Neurotoxicology (2012) 0.87
Environmental and dietary risk factors in Alzheimer's disease. Expert Rev Neurother (2007) 0.86
Transplacental effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the temporal modulation of Sp1 DNA binding in the developing cerebral cortex and cerebellum. Exp Toxicol Pathol (2002) 0.84
The ability of tolfenamic acid to penetrate the brain: a model for testing the brain disposition of candidate Alzheimer's drugs using multiple platforms. Curr Alzheimer Res (2011) 0.83
Co-localization and distribution of cerebral APP and SP1 and its relationship to amyloidogenesis. J Alzheimers Dis (2008) 0.83
Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm. Curr Alzheimer Res (2012) 0.83
Lead exposure: expression and activity levels of Oct-2 in the developing rat brain. Toxicol Sci (2006) 0.80
Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice. Neurobiol Aging (2013) 0.80
Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a pre-clinical evaluation. Cell Physiol Biochem (2013) 0.79
Ontogenetic alterations in prototypical transcription factors in the rat cerebellum and hippocampus following perinatal exposure to a commercial PCB mixture. Neurotoxicology (2005) 0.78
Characterization of nigerlysin, hemolysin produced by Aspergillus niger, and effect on mouse neuronal cells in vitro. Toxicology (2005) 0.77
An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients. Schizophr Res (2008) 0.75
Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies. J Neurochem (2014) 0.75